ClinicalTrials.gg
CompletedNCT04498169FuchsUpdated Sep 15, 2022Results posted

A Phase 2 Study Evaluating the Safety and Efficacy of Netarsudil Ophthalmic Solution in Patients With Corneal Edema Due to Fuchs Corneal Dystrophy

A Phase 2 interventional study of Netarsudil Ophthalmic and Netarsudil Ophthalmic in Corneal Edema, sponsored by Aerie Pharmaceuticals. Completed at 12 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-09-15.

Sponsored by Aerie Pharmaceuticals (part of Alcon) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 17 studies in Corneal Edema with a site in United States — 2 open to participants now, 3 under way, 1 of them phase 3. Corneal Edema · United States.

Enrollment
11th of 14
40 · median 61
Started
2020
with 1 other
Phase 2
2 of 17
1 open now
Registered
5th of 17
by date
Lead sponsor
1 of 17
Aerie Pharmaceuticals

Among the 17 studies in Corneal Edema with a site in United States, this one is the 11th largest by enrollment of the 14 interventional ones that give a count, is one of 2 that started in 2020, is one of 2 in phase 2, and was the 5th registered.

Corneal Edema

39 studies on the registry are indexed under Corneal Edema; 8 are open to participants now.

Browse Corneal Edema studies →

Open to participants now

2 of the 17 studies in Corneal Edema with a site in United States are open now. Recruiting first, the newest first:

All 2 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 6 Corneal Edema studies recruiting now, 5 set no upper age limit and none stop at 75 or younger; none take children under 18; none take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 17 studies in Corneal Edema with a site in United States, or all of them as a file.
02

Study summary

Two different dosing regimens (QD and BID) of netarsudil will be studied to evaluate their efficacy in reducing or resolving corneal edema in subjects with FCD.

03

Conditions studied

  • Corneal Edema

Keywords

  • Corneal Edema
  • Fuchs Corneal Dystrophy
  • Netarsudil Ophthalmic Solution
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Adults aged 18 years or older
  2. Documented diagnosis of FCD
  3. Evidence of central corneal edema, in at least one eye, at the Screening and Baseline Visit, in the eligible eye(s)
  4. Reduced BCVA secondary to central corneal edema, at Screening and Baseline, in the eligible eye(s)

Exclusion criteria

Exclusion Criteria:

  1. FCD so advanced that, in the opinion of the Investigator, surgery would likely be required in the study eligible eye(s) within the study period
  2. ocular disease (other than FCD) or trauma in the eligible eye(s) which could interfere with study interpretation
  3. History of ocular surgery within 6 months of the Screening Visit, or any prior corneal refractive surgery in the eligible eye(s)
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
40 participants (actual)

Study arms

  • Experimental
    Once Daily Netarsudil Ophthalmic Solution

    One drop of Netarsudil 0.02% ophthalmic solution in the study eye in the evening for an 8 week period in up to 20 subjects.

    Drug: Netarsudil Ophthalmic

  • Experimental
    Twice Daily Netarsudil Ophthalmic Solution

    One drop of Netarsudil 0.02% ophthalmic solution in the study eye in the morning and in the evening for an 8 week period in up to 20 subjects.

    Drug: Netarsudil Ophthalmic

Interventions

  • Netarsudil Ophthalmic Solution 0.02% Topical Sterile Ophthalmic Solution

    Also known as: Rhopressa®

  • Netarsudil Ophthalmic Solution 0.02% Topical Sterile Ophthalmic Solution

    Also known as: Rhopressa®

06

What researchers measure

Primary outcomes

  1. Central Corneal Thickness (CCT)

    Mean change from baseline in CCT by ultrasound pachymetry

    Time frame: Baseline & 4 weeks

07

Results

Posted Sep 1, 2022

Participant flow

Recruitment took place at 12 clinic sites in the United States between September 2020 and June 2021.

Modified Intent-to-Treat Population
Participant flow — Modified Intent-to-Treat Population
MilestoneOnce Daily Netarsudil Ophthalmic SolutionTwice Daily Netarsudil Ophthalmic Solution
Started2020
Completed1919
Not completed11
Safety Population
Participant flow — Safety Population
MilestoneOnce Daily Netarsudil Ophthalmic SolutionTwice Daily Netarsudil Ophthalmic Solution
Started2020
Completed1919
Not completed11
Per-Protocol Population
Participant flow — Per-Protocol Population
MilestoneOnce Daily Netarsudil Ophthalmic SolutionTwice Daily Netarsudil Ophthalmic Solution
Started1816
Completed1815
Not completed01
Study Completion
Participant flow — Study Completion
MilestoneOnce Daily Netarsudil Ophthalmic SolutionTwice Daily Netarsudil Ophthalmic Solution
Started2020
Completed1919
Not completed11
Withdrew: Adverse event11

Outcome measures

PrimaryCentral Corneal Thickness (CCT)

Mean change from baseline in CCT by ultrasound pachymetry

Time frame:
Baseline & 4 weeks
Reported as:
Mean · µm
Central Corneal Thickness (CCT)
µmOnce Daily Netarsudil Ophthalmic SolutionTwice Daily Netarsudil Ophthalmic Solution
Central Corneal Thickness (CCT)-28.4 ± 35.72-20.1 ± 39.12
Statistical analysis
  • Once Daily Netarsudil Ophthalmic Solution vs Twice Daily Netarsudil Ophthalmic Solution · One-sample t-test (within group) · p = 0.0021

Adverse events

Collected over Adverse events were documented from the time of signing the informed consent until the last study visit for each participant. This was a period of approximately 8 weeks (56 days) for participants who completed the full study duration. For AEs ongoing at the time of study completion, the ongoing AE was followed-up and the participant was provided appropriate medical care until the event resolved or stabilized, the participant was lost to follow-up, or there was other resolution to the event.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Once Daily Netarsudil Ophthalmic Solution0/20 (0%)0/20 (0%)5/20 (25%)
Twice Daily Netarsudil Ophthalmic Solution0/20 (0%)1/20 (5%)7/20 (35%)
Most frequent serious events
Most frequent serious events
EventOnce Daily Netarsudil Ophthalmic SolutionTwice Daily Netarsudil Ophthalmic Solution
Viral gastroenteritisGastrointestinal disorders0/201/20
Most frequent other events
Most frequent other events
EventOnce Daily Netarsudil Ophthalmic SolutionTwice Daily Netarsudil Ophthalmic Solution
Conjunctival hypaeremiaEye disorders2/204/20
Corneal verticillataEye disorders3/202/20
Erythema of eyelidEye disorders0/202/20

Baseline characteristics

40 participants were randomized; 20 each to the Netarsudil QD and the Netarsudil BID arms. 1 participant discontinued from each arm due to adverse events. 40 participants were included in both the mITT population for the primary endpoint analysis and the safety population for safety analysis. 6 participants were excluded from the per-protocol analysis due to protocol deviations (2 in the Netarsudil QD arm, 4 in the Netarsudil BID arm). There were no Covid-19 related protocol deviations.

Age, Categorical
Age, Categorical(Participants)Once Daily Netarsudil Ophthalmic SolutionTwice Daily Netarsudil Ophthalmic SolutionTotal
<=18 years000
Between 18 and 65 years9918
>=65 years111122
Sex: Female, Male
Sex: Female, Male(Participants)Once Daily Netarsudil Ophthalmic SolutionTwice Daily Netarsudil Ophthalmic SolutionTotal
Female91221
Male11819
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Once Daily Netarsudil Ophthalmic SolutionTwice Daily Netarsudil Ophthalmic SolutionTotal
Black/African American022
White201838
Region of Enrollment
Region of Enrollment(participants)Once Daily Netarsudil Ophthalmic SolutionTwice Daily Netarsudil Ophthalmic SolutionTotal
United States202040
08

Study locations

12 sites
  • Orange County Ophthalmology
    Garden Grove, California 92843, United States
  • Harvard Eye Associates
    Laguna Hills, California 92653, United States
  • Cincinnati Eye Institute
    Edgewood, Kentucky 41017, United States
  • Advance Eye Associates
    South Dartmouth, Massachusetts 02748, United States
  • Chu Vision Institute
    Bloomington, Minnesota 55420, United States
  • Minnesota Eye Care
    Minnetonka, Minnesota 55305, United States
  • Ophthalmology Associates
    Saint Louis, Missouri 63131, United States
  • Vance Thompson Vision
    W. Fargo, North Dakota 58078, United States
  • Comprehensive Eye Care
    Westerville, Ohio 43082, United States
  • Vance Thompson Vision
    Sioux Falls, South Dakota 57108, United States
  • Houston Eye Associates
    Houston, Texas 77025, United States
  • Virginia Eye Consultants
    Norfolk, Virginia 23502, United States
09

References and documents

Publications

  • Lindstrom RL, Lewis AE, Holland EJ, Sheppard JD, Hovanesian JA, Senchyna M, Hollander DA. Phase 2, Randomized, Open-Label Parallel-Group Study of Two Dosing Regimens of Netarsudil for the Treatment of Corneal Edema Due to Fuchs Corneal Dystrophy. J Ocul Pharmacol Ther. 2022 Dec;38(10):657-663. doi: 10.1089/jop.2022.0069. Epub 2022 Nov 3. PubMed 36327101 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Sep 2020 to primary completion in Aug 2021, 10 months.

Results were first posted in Sep 2022, 1 year after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 31, 2020
First posted
Aug 4, 2020
StartActual
Sep 17, 2020
Primary completionActual
Aug 11, 2021
CompletionActual
Aug 11, 2021
Results first posted
Sep 1, 2022
Last update
Sep 15, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 15, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04498169
Responsible party
Sponsor
First posted
Aug 4, 2020
Start date
Sep 17, 2020
Primary completion
Aug 11, 2021
Completion
Aug 11, 2021
Results posted
Sep 1, 2022
Last update
Sep 15, 2022

Study contacts

Michelle Senchyna, Ph.D.
study director · Aerie Pharmaceuticals Inc.

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Netarsudil

Start the discussion